Skip to main content
Book cover

Tumor Microenvironment

  • Book
  • © 2020

Overview

  • Discusses numerous aspects of immune landscapes and their biology
  • Explores the relation between the tumor microenvironment and therapy
  • Examines advances in imaging of the tumor microenvironment

Part of the book series: Cancer Treatment and Research (CTAR, volume 180)

This is a preview of subscription content, log in via an institution to check access.

Access this book

eBook USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 119.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (11 chapters)

  1. Imaging of Tumor Microenvironment

  2. Immune Landscapes and Their Biology

  3. The Tumor Microenvironment and Therapy

Keywords

About this book

This book addresses the biological processes relevant to the immune phenotypes of cancer and their significance for immune responsiveness, based on the premise that malignant cells manipulate their surroundings through an evolutionary process that is controlled by interactions with innate immune sensors as well as the adaptive recognition of self/non-self. Checkpoint inhibitor therapy is now an accepted new form of cancer treatment. Other immuno-oncology approaches, such as adoptive cell therapy and metabolic inhibitors, have also shown promising results for specific indications. Immune resistance is common, however, limiting the efficacy of immunotherapy in many common cancer types. 

The reasons for such resistance are diverse and peculiar to the immune landscapes of individual cancers, and to the treatment modality used. Accordingly, approaches to circumvent resistance need to take into account context-specific genetic, biological and environmental factors that may affect the cancer immune cycle, and which can best be understood by studying the target tissue and correlated systemic immune markers. 

Understanding the major requirements for the evolutionary process governing human cancer growth in the immune-competent host will guide effective therapeutic choices that are tailored to the biology of individual cancers.

Reviews


Editors and Affiliations

  • Department of Immuno-Oncology, City of Hope National Medical Center, Duarte, USA

    Peter P. Lee

  • Refuge Biotechnologies, Menlo Park, USA

    Francesco M. Marincola

About the editors

Peter P. Lee, M.D. is Billy and Audrey L. Wilder Endowed Professor in Cancer Immunotherapeutics, Chair of the Department of Immuno-Oncology, and Co-Leader of the Cancer Immunotherapeutics Program at the Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. Dr. Lee trained in clinical immunology at UCSF and hematology at Stanford University. Prior to joining City of Hope in 2011, he was a tenured faculty at Stanford. Dr. Lee has authored more than 100 peer-reviewed publications and trained over 20 pre- and postdoctoral fellows. He is an elected member of the American Society for Clinical Investigation (ASCI) and has been the recipient of various awards. Dr. Lee’s research focuses on understanding how the tumor microenvironment (TME) impacts host immune responses in cancer patients, with the goal of developing novel treatments to modulate the TME and restore/enhance immune function in these patients. He seeks to rationally integrate immunotherapies into combinations to achieve proper treatment sequencing and maximum clinical efficacy. 

Francesco Marincola, M.D. is currently Chief Scientific Officer at Refuge Biotechnologies, Menlo Park, California. He has previously served as a Distinguished Research Fellow at AbbVie Corporation in Redwood City, California; Chief Research Officer at Sidra Medical and Research Center in Doha, Qatar; and Tenured Investigator at the National Institutes of Health, Bethesda, Maryland. Dr. Marincola’s research interest lies in translational medicine and focuses on the development of strategies for the dynamic study of patients’ response to immunotherapy. His approach has resulted in seminal observations regarding the mechanisms leading to rejection of tumors, allograft rejection, graft-versus-host disease, and autoimmunity. In 2003, Dr. Marincola founded the Journal of Translational Medicine, of which he is currently the Editor-in-Chief. He is also Editor-in-Chief of Translational Medicine Communications and Clinical and Translational Medicine. He is a past president of both the Society for the Immunotherapy of Cancer (SITC) and the International Society for Translational Medicine. He has edited several biomedical books and is also an award-winning fiction writer.

Bibliographic Information

  • Book Title: Tumor Microenvironment

  • Editors: Peter P. Lee, Francesco M. Marincola

  • Series Title: Cancer Treatment and Research

  • DOI: https://doi.org/10.1007/978-3-030-38862-1

  • Publisher: Springer Cham

  • eBook Packages: Medicine, Medicine (R0)

  • Copyright Information: Springer Nature Switzerland AG 2020

  • Hardcover ISBN: 978-3-030-38861-4Published: 26 March 2020

  • Softcover ISBN: 978-3-030-38864-5Published: 26 March 2021

  • eBook ISBN: 978-3-030-38862-1Published: 25 March 2020

  • Series ISSN: 0927-3042

  • Series E-ISSN: 2509-8497

  • Edition Number: 1

  • Number of Pages: XXIV, 326

  • Number of Illustrations: 5 b/w illustrations, 56 illustrations in colour

  • Topics: Oncology, Immunology

Publish with us